TSNARE1: A Promising Drug Target and Biomarker for the Treatment of Neoplasia

Target Name: TSNARE1

NCBI ID: G203062

TSNARE1

TSNARE1: A Promising Drug Target and Biomarker for the Treatment of Neoplasia

Abstract:

TSNA1_HUMAN, a protein encoded by the human gene TSNARE1, has been identified as a potential drug target and biomarker for the treatment of neoplasia, a leading cause of cancer-related mortality worldwide. This protein plays a crucial role in the development and progression of cancer, and its dysfunction has been implicated in the development of numerous types of cancer. Therefore, the study of TSNARE1 and its potential as a drug target is of great interest and may have significant implications for cancer treatment.

Introduction:

Neoplasia, the formation of new tissue in a non- growing area, is a complex process that involves the activation of cell proliferation and the development of cancer. Neoplasia can occur in any part of the body and can be a highly aggressive and deadly form of cancer. The development of neoplasia is highly influenced by various factors, including genetic and environmental factors.

TSNA1_HUMAN:

TSNA1_HUMAN is a 21-kDa protein that is encoded by the human gene TSNARE1. The protein is involved in the formation of microtubules, which are essential for the proper functioning of cells. Microtubules are dynamic structures that play a crucial role in the transport of organelles, the production of cytokines, and the regulation of cell-cell interactions.

TSNA1_HUMAN is highly expressed in various tissues and has been implicated in the development and progression of various types of cancer. For example, high levels of TSNARE1 have been observed in various types of cancer, including breast, ovarian, and colorectal cancers. Additionally, TSNARE1 has been shown to be involved in the regulation of cell apoptosis, a process that is often associated with the development of cancer.

Drug Targeting:

TSNA1_HUMAN has been identified as a potential drug target for the treatment of neoplasia due to its involvement in the development and progression of cancer. The inhibition of TSNARE1 has been shown to have negative effects on the growth and survival of cancer cells.

TSNA1_HUMAN can be targeted by small molecules, antibodies, or other therapeutic agents that are designed to disrupt its function. For example, inhibitors of TSNARE1 have been shown to have therapeutic effects in various types of cancer, including breast, ovarian, and colorectal cancers. These inhibitors work by modulating the structure and function of TSNARE1, leading to the disruption of its role in the development and progression of cancer.

Biomarker:

TSNA1_HUMAN can also be used as a biomarker for the diagnosis and monitoring of cancer. The expression of TSNARE1 has been shown to be variable in different types of cancer, and its levels can be used as a biomarker for the detection and quantification of cancer.

TSNA1_HUMAN has been used as a biomarker in various types of cancer, including breast, ovarian, and colorectal cancers. Studies have shown that the expression of TSNARE1 is significantly altered in these types of cancer compared to the surrounding tissue. The levels of TSNARE1 have also been shown to be associated with the clinical outcomes of cancer patients, including their overall survival and response to chemotherapy.

Conclusion:

TSNA1_HUMAN is a protein that is involved in the development and progression of cancer. Its dysfunction has been implicated in the development of numerous types of cancer, including breast, ovarian, and colorectal cancers. Therefore, the study of TSNARE1 and its potential as a drug target is of great interest and may have significant implications for cancer treatment.

The inhibition of

Protein Name: T-SNARE Domain Containing 1

The "TSNARE1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TSNARE1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets